Nettis E, Di Paola R, Napoli G, Ferrannini A, Tursi A
Department of Clinical Immunology and Allergology, University of Bari, Piazza Giulio Cesare 11, 70124 Bari, Italy.
Allergy. 2002 May;57(5):442-5. doi: 10.1034/j.1398-9995.2002.13325.x.
Cutaneous adverse reactions to nonsteroidal anti-inflammatory drugs (NSAIDs), in particular urticaria/angiedema syndrome, represent a frequent problem in clinical practice. To date laboratory tests for the diagnosis of these adverse reactions are not available. A patient with an adverse drug reaction to NSAIDs needs an alternative drug to assume if necessary. Nimesulide is a highly prescribed nonsteroidal anti-inflammatory drug (NSAID) world-wide. It is also described as one of the most tolerated NSAID. In this paper we present data on the tolerability of benzydamine in nimesulide-sensitive patients.
One hundred and thirty-seven patients with nimesulide-induced urticaria were submitted to a single-blind, placebo-controlled peroral challenge with increasing doses of benzydamine.
One hundred and thirty-four out of 137 (98%) patients tolerated benzydamine without adverse effects, only three (2%) experienced immediate systemic urticaria (1 at the first dose and 2 at the second dose).
Benzydamine is a well tolerated drug in patients with nimesulide-induced urticaria and it may represent a valid alternative NSAID in nimesulide-sensitive patients.
非甾体抗炎药(NSAIDs)引起的皮肤不良反应,尤其是荨麻疹/血管性水肿综合征,是临床实践中常见的问题。迄今为止,尚无用于诊断这些不良反应的实验室检测方法。对NSAIDs有药物不良反应的患者在必要时需要更换其他药物。尼美舒利是一种在全球范围内被大量处方的非甾体抗炎药(NSAID)。它也被描述为耐受性最好的NSAID之一。在本文中,我们展示了关于苯海拉明在尼美舒利敏感患者中的耐受性数据。
137例尼美舒利诱发荨麻疹的患者接受了递增剂量苯海拉明的单盲、安慰剂对照口服激发试验。
137例患者中有134例(98%)耐受苯海拉明且无不良反应,只有3例(2%)出现即刻全身性荨麻疹(1例在首次给药时出现,2例在第二次给药时出现)。
苯海拉明在尼美舒利诱发荨麻疹的患者中耐受性良好,它可能是尼美舒利敏感患者有效的替代NSAID。